dpp 4 inhibitor and glp 1 agonist Clinical Use of DPP-4 Inhibitors Mechanisms of dipeptidyl peptidase‐4 (DPP‐4)
Description
Some patients may experience symptoms such as nausea, vomiting, diarrhea, and constipation
Their primary indication is the management of type 2 diabetes, where they are used alongside diet and exercise to improve glycaemic control by enhancing insulin secretion, suppressing glucagon, and supporting healthier glucose regulation 3 , 4
30 , e13313 (2018)
Effect of glucagon-like peptide-1 (proglucagon 78-107amide) on hepatic glucose production in healthy man
Bridgewater, NJ: sanofi-aventis U.S
Both GIPR and GLP-1R are expressed in overlapping brain regions including the ARC, PVN, and AP
